Last updated on June 2020

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Diabetes Mellitus Types I and II | Diabetes Mellitus | Diabetes (Pediatric) | Type 2 | Diabetes Prevention | NIDDM | Diabetes Mellitus Type 2
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Participants must have T2D based on the disease diagnostic criteria World Health Organization (WHO) classification.
  • Participants must have been treated for at least 90 days prior to screening with either basal insulin + at least 1 prandial injection of bolus insulin or premixed analog/human insulin regimens at least twice daily.
  • Participants must be treated no more than 3 oral anti-hyperglycemic medications (OAMs).
  • Participants must have a HbA1c 7.0% and 11.0%.
  • Participants must have body mass index (BMI) of 35.0 kilograms per meter squared (kg/m2).

Exclusion Criteria:

  • Participants must not have been diagnosed, at any time, with type 1 diabetes (T1D) or latent autoimmune diabetes in adults.
  • Participants must not have had any episode of severe hypoglycemia within the 6 months prior to screening.
  • Participants must not have had 1 or more episodes of diabetic ketoacidosis or hyperglycemic hyperosmolar state within the 6 months prior to screening.
  • Participants must not have used thiazolidinediones, glucagon-like peptide 1 (GLP-1) receptor agonist, or pramlintide within 90 days prior to screening.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.